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Abstract Glutathione S-transferases (GSTs) enzymes are in-
volved in conjugation of electrophilic compounds to glutathi-
one, and glutathione S-transferase T 1 (GSTT1) and
glutathione S-transferase M 1 (GSTM1) polymorphisms have
been implicated as risk factors for prostate cancer. We
conducted a systematic review and meta-analysis to define
the effect of GSTM1 and GSTT1 null genotypes on prostate
cancer risk in Asians. We searched the PubMed and Wanfang
Medical databases to identify published case–control studies
investigating the associations of GSTM1 and GSTT1 null
genotypes with risk of prostate cancer in Asians. Heterogene-
ity was assessed using Cochran’s Q statistic and odds ratios
(OR) with corresponding 95% confidence intervals (95 % CI)
from individual studies were pooled using fixed or random
effects models according to the heterogeneity. There were 18
studies (2,046 cases, 2,876 controls) on GSTM1 polymor-
phism, 15 studies (1,677 cases, 2,431 controls) on GSTT1
polymorphism, and 6 studies (675 cases, 853 controls) on
GSTM1/GSTT1 interaction analysis. Overall, GSTM1 null
genotype was significantly associated with increased risk of
prostate cancer in Asians (random effects OR 1.80, 95 % CI
1.48–2.18, P<0.001), and GSTT1 null genotype was also
significantly associated with increased risk of prostate cancer
in Asians (random effects OR 1.40, 95 % CI 1.10–1.80,
P<0.001). In addition, the GSTM1/GSTT dual null genotype
was associated with higher risk of prostate cancer in Asians
(random effects OR 2.14, 95 % CI 1.59–2.89, P=0.007). In
conclusion, GSTM1 and GSTT1 null genotypes are associat-
ed with increased risk of prostate cancer in Asians, and
GSTM1 and GSTT1 null genotypes are risk factors for the
development of prostate cancer.
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Introduction
Prostate cancer is a multifactorial disease, and its etiology in
detail is still not understood [1, 2]. Previous studies have
suggested that both environmental and genetic factors are
involved in the carcinogenesis of prostate cancer, and indi-
vidual difference in the susceptibility to carcinogens plays
an important role in the development of prostate cancer [3,
4]. The biochemical basis for the individual difference in the
susceptibility to carcinogens may be attributed to the genetic
polymorphisms of genes implicated in the metabolic detox-
ification of environmental carcinogens [3, 4]. Currently,
there are several important genes encoding enzymes in-
volved in the biotransformation of carcinogens, including
glutathione S-transferases (GSTs) enzymes [5, 6]. The GSTs
enzymes are involved in the metabolism of a wide variety of
potential carcinogens in conjugation of electrophilic com-
pounds to glutathione, and high level of GSTs enzymes is
important to protect DNA from damages by detoxifying the
electrophilic carcinogens [5, 6]. The expression of GSTs
enzymes is mainly affected by the genetic polymorphisms
in the GSTs genes [7, 8]. Previous studies have suggested
that individuals with null genotypes of glutathione S-
transferase M 1 (GSTM1) and glutathione S-transferase T
1 (GSTT1) may be unable to eliminate electrophilic carcin-
ogens efficiently and suffer from high risk of cancer [9].
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Therefore, it has been proposed that GSTT1 and GSTM1
polymorphisms are risk factors for prostate cancer [10–12].
However, the results from previous published studies in
Asians reported inconclusive findings [10–19]. Therefore,
we conducted a systematic review and meta-analysis to
define the effect of GSTM1 and GSTT1 null genotypes on
prostate cancer risk in Asians.
Material and methods
Study identification and eligibility criteria
We searched the PubMed and Wanfang Medical databases to
identify published case–control studies investigating the asso-
ciations of GSTM1 and GSTT1 null genotypes with risk of
prostate cancer in Asians. Computer searches were conducted
using relevant keywords (“GSTT1,” “GSTM1,” or “glutathi-
one S-transferase”) in combination with keywords (“prostate
cancer” and “prostate carcinoma”). There was no language
limitation. The reference lists of all relevant studies and re-
view articles were also scanned for other eligible studies.
Case–control studies that were performed to define the effect
of GSTM1 and GSTT1 null genotypes on prostate cancer risk
in Asians were eligible for inclusion. Family-based studies
were excluded owing to different design.
Data extraction
The following information was abstracted from each study:
first author, year of publication, study design, matching
factors, geographical locations, ethnicity of participants,
the definitions and numbers of cases and controls, source
of controls, genotyping methods, frequencies of
GSTM1/GSTT1 null genotypes, and normal genotypes.
Evidence synthesis
All associations were assessed using odds ratios (OR) with
the corresponding 95 % confidence interval (95 % CI).
Between-study heterogeneity was assessed using Cochran’s
Q statistic method [20]. The OR with corresponding 95 %
CI from individual studies were pooled using fixed or ran-
dom effects models according to the heterogeneity. When
the P value for Cochran’s Q statistic was less than 0.05, and
a significant heterogeneity existed across the included stud-
ies, the random effects model (DerSimonian and Laird
method) was used for meta-analysis [21], or else the fixed
effects model (Mantel–Haenszel method) was used [22].
Sensitivity analysis was further performed by excluding
single study in turn to assess the impact of individual study
on the pooled estimate. The possibility of publication bias
was assessed by visually assessing a funnel plot for
asymmetry and then assessed using the Egger’s test [23].
Statistical analyses were performed using STATA (version
11/SE, Stata Corp., College Stage Station, Texas).
Results
Eligible studies
Out of 86 studies retrieved by our initial literature search, 18
studies were considered eligible for this systematic review
and were included in the meta-analysis [10–19, 24–31].
There were 18 studies (2,046 cases, 2,876 controls) on
GSTM1 polymorphism, 15 studies (1,677 cases, 2,431 con-
trols) on GSTT1 polymorphism, and 6 studies (675 cases,
853 controls) on GSTM1/GSTT1 interaction analysis
[10–19, 24–31]. These 18 studies were conducted over a
period of 12 years (from 2001 to 2012) [10–19, 24–31]. In
general, studies were relatively small, and the mean number
of cases was 113.7 (range, 50–208) and the mean number of
controls was 159.8 (range, 46–336). Most of these 18 stud-
ies matched cases to controls by age and gender. The fre-
quency of the GSTM1 null genotype among controls in
these 18 studies ranged from 10.0 to 55.4 %, while the
frequency of the GSTT1 null genotype among controls in
these 18 studies ranged from 11.1 to 53.3 % [10–19, 24–31].
Evidence synthesis
There was obvious between-study heterogeneity among these
included studies in the meta-analyses of the associations be-
tween prostate cancer and GSTM1 null genotype (P<0.001)
and GSTT1 null genotype (P<0.001), but there was no
between-study heterogeneity among these included studies
on GSTM1/GSTT1 interaction analysis (P=0.992). Overall,
GSTM1 null genotype was significantly associated with in-
creased risk of prostate cancer in Asians (random effects OR
1.80, 95 % CI 1.48–2.18, P<0.001), and GSTT1 null geno-
type was also significantly associated with increased risk of
prostate cancer in Asians (random effects OR 1.40, 95 % CI
1.10–1.80, P<0.001) (Figs. 1 and 2). In addition, the
GSTM1/GSTT dual null genotype was associated with higher
risk of prostate cancer in Asians (random effects OR 2.14,
95 % CI 1.59–2.89, P=0.007) (Fig. 3). Sensitivity analysis by
excluding single study in turn showed that there were no
obvious changes on the pooled estimates after excluding any
single study.
Risk of bias
There was no obvious evidence of asymmetry in the funnel
plots of this meta-analysis (figures not shown). In addition,
the outcomes from Egger’s test further showed statistical
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evidence of symmetry in the funnel plots (PGSTM1=0.652,
PGSTT1=0.452, PGSTM1/GSTT1=0.327). Therefore, there was
no obvious risk of publication bias in this meta-analysis.
Discussion
GSTs are members of biotransformation enzymes, and they
are phase II enzymes with both catalytic activities and
noncatalytic functions [7]. Besides, GSTs are involved in
the detoxification of electrophilic compounds by glutathione
conjugation, such as carcinogens and cytotoxic drugs [6, 7].
Since the presumed function of GSTs is to protect tissues
against toxic and carcinogenic compounds, they are thought
to be important determinants in the development of prostate
cancer. Previous studies have shown that individuals with
GSTM1 null genotype have a decreased capacity to detoxify
certain carcinogens, and it is the same with individuals with
GSTT1 null genotype [9].
Prostate cancer is a multifactorial disease, and its etiology
in detail is still not understood [4, 32, 33]. Previous studies
have suggested that both environmental and genetic factors
are involved in the carcinogenesis of prostate cancer, and
individual difference in the susceptibility to carcinogens
plays an important role in the development of prostate
cancer. The biochemical basis for the individual difference
in the susceptibility to carcinogens may be attributed to the
genetic polymorphisms of genes implicated in the metabolic
detoxification of environmental carcinogens. Previous stud-
ies have suggested that individuals with null genotypes of
GSTM1 and GSTT1 may be unable to eliminate electrophil-
ic carcinogens efficiently and suffer from high risk of can-
cer, and it has been proposed that GSTT1 and GSTM1
polymorphisms are risk factors for prostate cancer. Howev-
er, the results from previous published studies in Asians
reported inconclusive findings [2–4, 18, 19, 26–33].
In the present meta-analysis, we conducted the first sys-
tematic review and meta-analysis to define the effect of
GSTM1 and GSTT1 null genotypes on prostate cancer risk
in Asians. There were 18 studies (2,046 cases, 2,876 controls)
on GSTM1 polymorphism, 15 studies (1,677 cases, 2,431
controls) on GSTT1 polymorphism, and 6 studies (675 cases,
853 controls) on GSTM1/GSTT1 interaction analysis [10–19,
24–31]. Overall, GSTM1 null genotype was significantly
NOTE: Weights are from random effects analysis































































Fig. 1 Forest plot for the meta-analysis of GSTM1 null genotype with
prostate cancer risk using random effects model. Each study is shown
by the point estimate of the odds ratio (square proportional to the
weight of each study) and 95 % confidence interval of the odds ratio
(extending lines); the pooled odds ratio and 95 % confidence intervals
are depicted as a diamond
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associated with increased risk of prostate cancer in Asians
(Fig. 1), and GSTT1 null genotype was also significantly
associated with increased risk of prostate cancer in Asians
(Fig. 2). In addition, the GSTM1/GSTT dual null genotype
NOTE: Weights are from random effects analysis






















































Fig. 2 Forest plot for the meta-analysis of GSTT1 null genotype with prostate cancer risk using random effects model



























Fig. 3 Forest plot for the meta-analysis of GSTM1/GSTT dual null genotype with prostate cancer risk using fixed effects model
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was associated with higher risk of prostate cancer in Asians
(Fig. 3). Therefore, the findings from this meta-analysis
showed that GSTM1 and GSTT1 null genotypes are associ-
ated with increased risk of prostate cancer in Asians.
This report is the first meta-analysis examining the effect of
GSTT1 and GSTM1 polymorphisms on the risk of prostate
cancer in Asians. The findings from this meta-analysis also
provide evidence for the important roles of GSTs in the
development of common cancers. In addition, the GSTT1
and GSTM1 polymorphisms have been proven as risk factors
for the development of many kinds of cancers [34–38]. Cur-
rently, there are convincing associations between GSTM1 null
genotype and risks of colorectal and liver cancer [38, 39].
However, other studies have not confirmed the association
between the GSTT1 null genotype and risks of ovarian and
oral cancers [34, 36]. The different associations between
GSTT1 and GSTM1 polymorphisms and risk of various kinds
of cancers suggest that GSTT1 and GSTM1 polymorphisms
may have different roles in the development of cancers.
In conclusion, GSTM1 and GSTT1 null genotypes are
associated with increased risk of prostate cancer in Asians,
and GSTM1 and GSTT1 null genotypes are risk factors for
the development of prostate cancer.
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